SK Biopharm Moves Into Radiopharma Via $572m Full-Life Deal

Part Of New Modality Focus

 
• By Jung Won Shin

After acquiring a majority stake in ProteoVant last year, South Korea's SK Biopharm is continuing to hunt for new modalities and is now moving into the hot radiotherapeutics area through a deal with Full-Life Technologies.

growth strategy
SK Biopharm To Announce Radiopharma Plans This Year • Source: Shutterstock

More from Deals

More from Business